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who  present  at  emergency  departments  early  after  chest  pain  onset  and  the  risk  stratiﬁcation
of patients  with  heart  failure.  The  purpose  of  this  article  is  to  review  the  data  on  the  place  of
copeptin in  the  management  of  patients  with  chest  pain  or  heart  failure.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Le  développement  de  plusieurs  marqueurs  a  radicalement  modiﬁé  la  prise  en  charge
des pathologies  cardiovasculaires  ces  20  dernières  années.  Récemment,  plusieurs  études  ont
évalué l’intérêt  diagnostique  et  pronostique  de  la  copeptine,  notamment  dans  le  contexte  de
l’insufﬁsance  cardiaque  et  du  syndrome  coronaire  aigu.  Les  premiers  résultats  sont  prometteurs
faisant de  la  copeptine  un  biomarqueur  particulièrement  intéressant  dans  l’amélioration  de  la
prise en  charge  aux  urgences  des  patients  se  présentant  avec  une  douleur  thoracique,  d’une
part, et  dans  la  stratiﬁcation  du  risque  des  patients  atteints  d’une  insufﬁsance  cardiaque,
d’autre  part.  L’objectif  de  cet  article  est  de  revenir  sur  les  données  disponibles  sur  la  copeptine
dans le  domaine  de  l’insufﬁsance  cardiaque  et  dans  le  domaine  de  la  douleur  thoracique  aux
urgences.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Over  the  past  two  decades,  the  introduction  of  multiple
biomarkers  has  changed  the  landscape  of  cardiovascular  dis-
eases,  especially  in  the  management  of  patients  with  acute
coronary  syndromes  (ACS)  and  heart  failure  (HF).  Biomark-
ers  can  provide  useful  information  for  diagnostic,  prognostic
and  therapeutic  strategies.
In  patients  with  chest  pain,  the  predominant  problem  in
clinical  practice  is  to  conﬁrm  or  rule  out  a  diagnosis  of  ACS
as  quickly  as  possible.  This  is  important  because:
• a  high  number  of  patients  are  referred  to  emergency
departments  (ED)  due  to  suspected  ACS;
• it is  necessary  to  start  early  medical  and/or  invasive  ther-
apies  in  actual  ACS  patients  in  order  to  improve  their
prognosis.
Multiple  biomarkers  —  including  myoglobin,  creatine
phosphokinase  (CPK)  and  CPK-MB  —  have  been  used  in  the
past,  but  their  delayed  release  after  myocardial  necro-
sis  and/or  their  lack  of  speciﬁcity  render  them  poorly
exploitable  in  clinical  practice  and  compromise  their  diag-
nostic  performance.  Currently,  troponin  assessment  is  the
gold  standard  for  the  early  detection  of  myocardial  infarc-
tion  (MI)  and  this  has  shown  better  aptitude  (sensitivity,
speciﬁcity,  early  detection)  compared  to  older  biomarkers.
However,  conventional  troponin  elevation  usually  still  occurs
relatively  late  (3—6  hours)  after  ACS  onset,  and  multiple
samplings  are  often  required  and  recommended  in  those
patients  who  present  early  (within  3  hours)  after  chest  pain
onset  (CPO)  [1—4].  In  addition,  since  the  recent  introduc-
tion  of  high-sensitivity  troponin,  there  has  been  an  increase
in  sensitivity  and  an  improvement  in  early  detection,  but  a
decrease  in  speciﬁcity  in  ACS  management.  Indeed,  many
causes  (e.g.  ACS,  acute  HF,  pulmonary  embolism,  myocardi-
tis  and  severe  sepsis)  could  lead  to  myocardial  necrosis  and,
subsequently,  to  increased  troponin  levels  in  practice  [5].
s
g
aIn  contrast  to  ACS,  in  HF  management,  the  major  issue  is
he  prognostic  evaluation  of  patients  with  chronic  HF  rather
han  the  diagnosis  of  acute  HF.  Indeed,  B-type  natriuretic
eptide  (BNP)  and  N-terminal  pro-hormone  BNP  (NT-proBNP)
ave  shown  to  be  highly  speciﬁc  of  HF  and  have  drastically
impliﬁed  the  management  of  patients  referred  to  ED  for
yspnoea  or  suspected  HF  [6—10]. By  contrast,  risk  stratiﬁ-
ation  remains  a  critical  issue  in  HF  management.  Indeed,
igh-risk  patients  can  therefore  be  considered  for  invasive
trategies  such  as  implantable  assist  devices  and/or  cardiac
ransplantation.  Variables  such  as  New  York  Heart  Associa-
ion  (NYHA)  class,  right  and  left  ventricular  functions,  BNP
r  variables  obtained  during  cardiopulmonary  exercise  test-
ng  (e.g.  VO2 max)  have  been  associated  with  the  outcome
f  chronic  HF  patients  [8].  In  spite  of  these  advances,  risk
tratiﬁcation  of  chronic  HF  patients  needs  further  improve-
ent.  Indeed,  there  remains  variability  in  prognosis,  with
ome  patients  categorized  as  low  risk  who  experience  early
ajor  cardiac  events  and  others  categorized  as  high-risk
ho  do  not.  In  addition,  since  cardiopulmonary  exercise
esting  is  a  time-consuming  method  that  is  rarely  used  for
isk  stratiﬁcation  in  routine  practice,  some  potent  indica-
ors  may  be  lacking  for  an  individual.  As  a  consequence,
here  is  a  critical  need  for  tools  that  may  help  physicians  to
uide  therapeutic  options  in  chronic  HF,  especially  to  bet-
er  select  patients  who  should  be  considered  for  invasive
trategies.
Therefore,  new  biomarkers  that  can  provide  addi-
ional  information  may  be  of  great  interest  in  clinical
ractice  to  help  physicians’  decisions  [11,12]. Copeptin,
 surrogate  for  arginine  vasopressin  (AVP)  secretion  is
 novel  biomarker  that  has  shown  great  potential  in
ardiovascular  diseases,  especially  ACS  and  chronic  HF.
n  this  review,  we  summarize  the  results  of  the  main
tudies  that  have  investigated  the  diagnostic  and  pro-
nostic  performances  of  copeptin  in  the  settings  of  ACS
nd  HF.
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A00  
he roles of AVP and copeptin
VP  (also  known  as  antidiuretic  hormone  [ADH])  is  synthe-
ized  in  the  hypothalamus  as  a  pre-pro-hormone,  and  is  then
ransported  to  the  neurohypophysis.  It  is  released  into  the
loodstream  from  the  posterior  pituitary  gland  in  response
o  changes  in  plasma  osmolarity  and  reduced  cardiac  output.
VP  levels  increase  with  most  acute  illnesses  and/or  stress
nd  play  crucial  roles  in  acute  HF  and  osmoregulation.  The
ypoperfusion  of  peripheral  organs  leads  to  AVP  secretion
n  order  to  maintain  circulatory  homeostasis  by  promoting
enal  water  reabsorption  via  the  vasopressin  V2 receptors
ocated  on  the  basolateral  membrane  of  collecting  duct  cells
f  the  kidney.  Binding  to  these  receptors,  it  activates  adeny-
ate  cyclase  and  leads  to  the  generation  of  cyclic  adenosine
onophosphate  (cAMP),  thus  decreasing  water  clearance  by
oving  the  aquaporin  2  channels  from  the  cytosol  to  the  cel-
ular  surface.  Enhanced  expression  of  aquaporin  channels  in
he  kidney  contributes  to  the  development  of  oedema  and
yponatraemia.  Vasopressin  coupling  to  V1 receptors  leads
o  an  activation  of  the  phosphatidylinositol  pathway  and
obilization  of  cytosolic  calcium.  Two  subtypes  exist:  V1a
eceptors  on  various  cell  types  (e.g.  heart  and  vessels)  and
1b in  the  anterior  pituitary.  V1a stimulation  in  the  arterial
ystem  leads  to:
vasoconstriction  and  cardiac  remodelling  (by  increasing
afterload);
decreased  systemic  vascular  resistance;
increased  cardiac  output  [13,14].
The  mechanism  of  action  of  AVP  is  shown  in  Fig.  1.
The  direct  role  of  AVP  in  chronic  HF  is  not  fully  under-
tood.  AVP  is  a  regulator  of  ﬂuid  dynamics  and  an  indicator
f  adequate  hypothalamo-pituitary-adrenal  axis  activation.
obust  data  have  shown  that  AVP  is  related  to  HF  severity
nd  outcomes  [15].  During  stress,  AVP  stimulation  results
n  adrenocorticotropic  hormone  and  cortisol  secretion.  AVP
iomarkers  have  previously  been  shown  to  be  rapid  markers
f  individual  stress  levels,  with  good  correlation  with  mod-
rate  stress  [16].  Because  many  clinical  situations  induce
ctivation  of  the  hypothalamic  stress  axis,  especially  in  car-
iovascular  disease,  AVP  markers  will  have  a  low  speciﬁcity
ut  a  high-sensitivity  for  individual  disease  such  as  ACS.
owever,  AVP  is  unstable  (short  half-life  and  90%  bound  to
latelets)  so  it  is  not  a  reliable  marker.
Copeptin,  the  C-peptide  portion  of  pre-pro-vasopressin
Fig.  2),  is  a  39-amino  acid  glycoprotein  that  is  more  sta-
le  than  AVP,  and  is  secreted  in  equimolar  amounts.  The
xact  function  of  copeptin  is  unknown.  This  peptide  is  easily
easurable  in  peripheral  blood,  and  represents  a  surrogate
arker  for  AVP  release  in  various  clinical  situations  [17—19].
t  has  emerged  as  a  potential  biomarker  in  various  cardiac
iseases  such  as  HF  and  ACS.
opeptin in ACS
he  diagnosis  and  risk  stratiﬁcation  in  patients  presenting
ith  suspected  non-ST  elevation  ACS  (NSTE-ACS)  usually  rely
n  cardiac  troponins  (I  and  T)  as  biomarkers  [1,2]. Troponins
re  currently  considered  the  gold  standard  for  the  detection
f  myocardial  necrosis;  they  have  also  been  shown  to  be
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trong  indicators  of  prognosis  in  this  setting  [3,4,20].  Nev-
rtheless,  the  major  weakness  of  these  biomarkers  is  their
elayed  release  after  cell  necrosis  that  consequently  alters
heir  diagnostic  performance  early  after  CPO.  Owing  to  the
igh  proportion  of  patients  who  present  in  ED  with  suspected
CS,  new  troponin  assays  have  been  developed  to  overcome
his  major  limitation.  High-sensitivity  troponins  allow  earlier
etection  and  have  shown  superiority  in  ACS  diagnosis  com-
ared  to  conventional  troponins  [21,22].  As  a  consequence,
igh-sensitivity  troponins  are  now  used  as  the  reference  for
atients  presenting  with  chest  pain  and/or  suspected  ACS
21,22].  However,  copeptin,  by  its  independent  pathophysi-
logy  and  its  rapid  release  after  ACS,  could  further  improve
iagnostic  accuracy  in  this  setting.
opeptin and prognosis in ACS
opeptin  has  ﬁrst  been  studied  in  order  to  investigate  its
rognostic  potential  in  ACS  (Table  1).  In  patients  presenting
ith  MI,  copeptin  has  been  shown  to  be  a  strong  predictor  of
orse  outcome  and  a  prognostic  marker  of  death  [20,23].  Of
ote,  its  relevance  was  increased  when  used  in  combination
ith  other  biomarkers  (NT-proBNP  and  troponins)  [20,23].
he  pathophysiological  background  of  troponins,  natriuretic
eptides  and  copeptin  reﬂects  different  characteristics  of
ardiac  homeostasis.  Therefore  a  combination  of  biomarkers
ay  give  more  information  than  a unique  biomarker  [23].
thers  studies  have  shown  that  copeptin  can  predict  left
entricular  dysfunction  and  clinical  events  related  to  HF  in
urvivors  of  MI  [20,24—27].
opeptin and diagnosis in ACS
ecently,  several  authors  have  focused  on  the  diagnostic
erformance  of  copeptin  in  the  setting  of  NSTE-ACS  and
hest  pain.  As  endogenous  stress  is  increased  at  the  onset
f  ACS,  copeptin  could  identify  ACS  patients  when  other
iomarkers  are  still  negative.  The  use  of  a  ‘dual-marker’
trategy  in  order  to  rapidly  rule  out  a  diagnosis  of  ACS  in
atients  presenting  with  chest  pain  has  been  studied  in
everal  large  trials  (Table  2) [28—32].  It  should,  however,
e  emphasized  that  most  large  studies  have  used  conven-
ional  troponins  as  a  reference  rather  than  high-sensitivity
roponins.
The  ﬁrst  study  that  tested  the  additional  diagnostic
erformance  of  copeptin  in  early  evaluation  of  patient  pre-
enting  with  suspected  ACS  was  conducted  by  Reichlin  et  al.
29]. In  their  study,  which  included  487  patients  with  sus-
ected  ACS  (within  12  hours  after  symptom  onset),  they
eport  that  the  combination  of  copeptin  and  troponin  T
mproved  the  area  under  the  receiver  operator  characteris-
ics  curve  from  0.86  to  0.97  (compared  to  troponin  alone)  for
he  diagnosis  of  MI.  In  addition,  negativity  of  both  biomark-
rs  (troponin  T  <0.01  g/L  and  copeptin  <14  pmol/L)  had  a
ensitivity  of  98.8%  and  a  negative  predictive  value  (NPV)  of
9.7%  to  correctly  rule  out  ACS.
In  2010,  Keller  et  al.  [30]  published  concordant  results.
ltogether,  1386  patients  with  suspected  ACS  were  enrolled
n  this  multicentre  study.  Blood  samples  and  electrocardio-
rams  (ECGs)  were  obtained  at  admission  and  after  3  and
 hours.  In  this  study,  37.3%  of  the  cohort  had  CPO  <3  hours,
8.2%  <6  hours  and  73.4%  <12  hours  [30].  The  diagnosis  of
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Figure 1. Mechanism of action of arginine vasopressin (AVP). AQ2: aquaporin 2 channel; AQwcv: aquaporin water channel containing
vesicles; cAMP: cyclic adenosine monophosphate; cCa2+: cytosolic calcium; Gq: G coupled protein q; Gs: G coupled protein s; H2O: water;
: pho
a
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s
p
a
N
w
i
tIP3: phosphatidyl inositol triphosphate; PKA: protein kinase A; PLC
receptor.
ACS  was  excluded  in  65.2%  of  patients,  while  a  discharge
diagnosis  of  MI  was  made  in  21.6%  of  patients.  In  the  sub-
group  of  patients  with  CPO  <3  hours  (those  patients  who  may
beneﬁt  the  most  from  copeptin  evaluation),  conventional
troponin  levels  rose  signiﬁcantly  during  the  ﬁrst  6  hours  after
admission  (P  <  0.001)  while  copeptin  levels  decreased  from
its  peak  (at  admission)  during  the  same  period  (P  <  0.001).
In  the  whole  population,  levels  of  troponin  reached  a  max-
imum  12  hours  after  CPO  in  MI  patients.  In  contrast,  the
copeptin  level  was  ﬁve  times  higher  when  CPO  was  <3  hours,
and  decreased  12  hours  after  CPO.  The  authors  showed  that
the  diagnostic  value  of  troponin  increased  over  time  after
CPO,  but  copeptin  had  the  strongest  diagnostic  performance
i
h
wspholipase C ; V1R: vasopressin V1 receptor; V2R: vasopressin V2
nd  discriminatory  power  in  patients  with  CPO  <3  hours.  A
ombination  of  troponin  T  and  copeptin  resulted  in  higher
ensitivity  and  NPV.  The  association  of  copeptin  with  tro-
onin  I  (more  sensitive  than  troponin  T,  but  not  as  sensitive
s  high-sensitivity  troponin)  further  improved  sensitivity  and
PV  (98.3  and  99.0%  respectively)  in  patients  presenting
ithin  3  hours  after  CPO  but  at  the  cost  of  reduced  pos-
tive  predictive  value  (PPV)  and  speciﬁcity.  In  conclusion,
he  authors  suggested  that  the  use  of  troponin  and  copeptin
mproves  diagnostic  performance,  especially  within  the  ﬁrst
ours  after  CPO.
The  Copeptin  Helps  in  the  early  detection  Of  Patients
ith  acute  myocardial  Infarction  (CHOPIN)  trial  [31]
402  G.  Schurtz  et  al.
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tigure 2. Structure of pre-pro-vasopressin. Vasopressin (positio
26—164) are highlighted. The ﬁrst 19 amino acids are the signal se
ncluded  1967  patients  who  presented  with  CPO  <6  hours
n  a  16-centre  prospective  study.  The  hypothesis  was  that
 copeptin  level  <14  pmol/L  at  admission  in  association
ith  conventional  troponin  I  and  an  ECG  would  rule  out
he  diagnosis  of  ACS  in  patients  presenting  with  chest
ain.  Of  these  patients,  75%  presented  within  3  hours  of
ymptom  onset.  The  ﬁnal  diagnoses  were  ACS  (14.4%),
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Table  1  Major  studies  focusing  on  the  prognostic  value  of  cop
Reference  Patients  Endpoint  and  res
O’Malley  et  al.,  2014  [20]  4432  patients
with  NSTE-ACS
To  assess  the  pro
peptides  and  car
Follow-up:  1  yea
Cardiac  troponin
Copeptin  was  ass
1.10—2.11)  and  H
1.17,  95%  CI:  0.8
Additional  value  
Khan  et  al.,  2007  [23] 980  MI
patients
To  assess  the  pro
peptides
Follow-up:  342  d
Copeptin  was  pre
95%  CI:  1.55—3.4
Stronger  predicti
Kelly  et  al.,  2008  [24]  274  MI
survivors
Association  betw
Follow-up:  155  d
Copeptin  predict
post-MI  patients  
Voors  et  al.,  2009  [26]  224  patients
with  HF  after
MI
Investigate  the  p
Follow-up:  1  yea
Multivariate  anal
with  mortality  (O
Reinstadler  et  al.,  2003  [25]  54  STEMI
patients
Correlation  betw
CMR)
Follow-up:  4  mon
High  copeptin  le
adverse  remodel
BNP: B-type natriuretic peptide; CI: conﬁdence interval; CMR: cardiac 
ventricular; LVEF: left ventricular ejection fraction; MI: myocardial in
NT-proBNP: N-terminal pro-hormone B-type natriuretic peptide; OR, od—28), neurophysin II (positions 32—124) and copeptin (positions
ce.
ardiovascular  non-ACS  (21.0%),  a  non-cardiac  diagnosis
30.5%)  and  unclassiﬁed  cause  (34.2%).  Of  note,  65.5%  of
he  patients  experienced  chest  pain  lasting  >30  minutes.
mong  ACS  patients  who  had  a  normal  troponin  I value  at
dmission,  copeptin  was  elevated  (median  129.2  pmol/L  for
T-segment  elevation  MI  [STEMI]  and  17.8  pmol/L  for  non-
T  elevation  MI  [NSTEMI]),  whereas  it  was  low  (8.7  pmol/L)
eptin  in  ACS  patients.
ults
gnostic  value  of  copeptin  compared  to  natriuretic
diac  troponin
r
 I  was  the  strongest  predictor  of  all  events
ociated  with  cardiovascular  mortality  (HR:  1.52,  95%  CI:
F  (HR:  1.70,  95%  CI:  1.18—2.43),  but  not  with  MI  (HR:
9—1.54)  after  adjustment  for  cofounders
on  top  of  BNP  and  cardiac  troponin  I
gnostic  value  of  copeptin  compared  to  natriuretic
ays
dictive  of  the  primary  endpoint  (death  or  HF;  OR:  2.33,
9)
on  when  added  to  NT-proBNP
een  copeptin  levels  and  LV  function  or  HF
ays
ed  LV  dysfunction  and  clinical  events  related  to  HF  in
(OR:  3.01,  95%  CI:  1.10—8.21)
rognostic  value  of  copeptin  on  mortality  and  morbidity
r
ysis  showed  that  copeptin  was  independently  correlated
R:  1.83,  95%  CI:  1.26—2.64)
een  copeptin  and  infarct  size  or  myocardial  function  (by
ths
vels  correlated  with  lower  LVEF,  greater  infarct  size  and
ling
magnetic resonance; HF; heart failure; HR: hazard ratio; LV: left
farction; NSTE-ACS: non-ST elevation acute coronary syndromes;
ds ratio; STEMI: ST-segment elevation myocardial infarction.
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Table  2  Major  studies  focusing  on  the  diagnostic  value  of  copeptin  in  ACS  patients.
Reference  Patients  Troponin  assay  High-
sensitivity
troponin?
Endpoint  and  results
Reichlin  et  al.,  2009  [29]  487  patients
with
suspected  ACS
Troponin  T  No  Improvement  of  the  AUC  from  0.86  using
troponin  alone  to  0.97  using  troponin
plus  copeptin  for  the  diagnosis  of  MI
Negativity  of  both  copeptin  and  troponin
had  a  high-sensitivity  (98.8%)  and  NPV
(99.7%)
Keller  et  al.,  2010  [30]  1386  patients
with
suspected  ACS
Troponins  T
and  I
No  Copeptin,  alone  and  especially  when
added  with  troponin,  improved
diagnostic  performance  with
high-sensitivity  (98.3%)  and  NPV  (99.0%)
in  patients  presenting  early  after  CPO
Maisel  et  al.,  2013  [31]  1967  patients
presenting
with  chest
pain  at  ED
Troponin  I  No  Negativity  of  both  copeptin  and  troponin
and  a  non-diagnostic  ECG  had  a
high-sensitivity  (92.2%)  and  NPV  (99.2%),
allowing  AMI  to  be  ruled  out  early  in  58%
of  patients  with  no  additional  blood
sample,  reducing  time  to  decision  from
2.96  to  1.80  hours
Mockel  et  al.,  2015  [32] 902  suspected
ACS
Troponin  T  in  6
sites
Troponin  I  in  1
site
Yes  in  6
sites
No  in  1  site
Prospective,  randomized  controlled  trial
comparing  standard  care  versus  standard
care  +  copeptin  (early  discharge  if
negative)
Follow-up:  30  days
In  the  copeptin  group,  discharged
copeptin-negative  patients  had  a  very
low  event  rate  (0.6%)
Proportion  of  MACE  was  similar  in  both
groups  (standard  care  versus  copeptin
group:  5.17%  versus  5.19%)
ACS: acute coronary syndromes; AMI: acute myocardial infarction; AUC: area under the receiver operator characteristic curve; CPO:
chest pain onset; ECG: electrocardiogram; ED: emergency department; MACE: major adverse cardiac events; NPV: negative predictive
value.
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tfor  other  diagnosis.  Copeptin  was  also  elevated  in  ACS
patients  whose  troponin  I  at  admission  was  elevated.  Tro-
ponin  I  levels  peaked  at  8—10  hours,  while  copeptin  levels
peaked  at  0—2  hours.  For  patients  without  MI,  both  markers
remained  low  throughout  0—30  hours.  The  NPV  of  a  normal
troponin  I  value  associated  with  a  non-diagnostic  ECG  and  a
copeptin  level  <14  pmol/L  was  excellent  (99.2%);  sensitivity
was  92.2%  and  speciﬁcity  was  62.6%.  Interestingly,  nega-
tivity  of  both  markers  allowed  physicians  to  rule  out  ACS
in  58%  of  patients  with  no  additional  blood  samples,  thus
reducing  the  time  to  decision  from  2.96  to  1.80  hours.  The
authors  concluded  that  the  combination  of  copeptin  and  tro-
ponin  I  at  admission  provides  a  strong  NPV  and  allows  the
avoidance  of  additional  biological  testing,  thus  improving
decision-making  in  patients  with  chest  pain  presenting  at
ED.The  BiC-8  study  [32]  is  probably  the  most  relevant
copeptin  biomarker  study  as  it  was  a  large-scale  randomized
trial  and  high-sensitivity  troponin  was  used  as  a  reference.
(
i
rt  was  the  ﬁrst  prospective,  randomized  study  to  assess  the
afety  of  an  early  discharge  after  ruling  out  MI  with  a  sin-
le  combined  test  of  high-sensitivity  troponin  and  copeptin.
ltogether,  902  patients  with  signs  and  symptoms  of  ACS
nd  negative  troponin  were  randomized  1:1  to  standard
are  (n  =  451)  or  a  new  process  that  incorporated  copeptin
n  =  451).  STEMI  patients  were  excluded,  as  were  those
ho  required  hospitalization.  Copeptin  was  measured  at
dmission,  and  a  value  ≥10  pmol/L  was  considered  positive.
atients  with  negative  troponin  and  negative  copeptin  were
ischarged  into  ambulant  care.  The  primary  endpoint  was
he  proportion  of  combined  major  adverse  cardiac  events
MACE)  within  30  days.  Of  note,  43.2%  of  patients  had  CPO
3  hours,  54.8%  <6  hours  and  64.0%  <12  hours.  Around  40%
f  the  patients  were  discharged  early  from  ED:  67.6%  in
he  copeptin  group  and  12.0%  in  the  standard  care  group
P  <  0.001).  The  use  of  copeptin  as  a  biomarker  did  not
mpact  on  the  ﬁnal  diagnosis  in  this  study.  NSTE-ACS  was
etained  as  the  ﬁnal  diagnosis  in  90  patients  (19.9%)  in
404  
Figure 3. Sensitivities (Se), speciﬁcities (Sp), positive predictive
values (PPV) and negative predictive values (NPV) for the diagnosis
of acute coronary syndromes (ACS) with cardiac troponin, alone and
in combination with copeptin, and high-sensitivity cardiac troponin
T, alone and in combination with copeptin.
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class  (P  =  0.0005),  glomerular  ﬁltration  rate  (P  =  0.0005),
systolic  blood  pressure  (P  =  0.0055)  and  female  genderdapted from the data of Raskovalova et al. [33].
he  standard  group  and  96  patients  (21.3%)  in  the  copeptin
roup,  which  was  not  statistically  different.  During  the  30-
ay  follow-up,  46  patients  experienced  a  MACE  (5.2%  in
oth  groups).  The  use  of  copeptin  allowed  physicians  to  dis-
harge  patients  without  ACS  earlier,  and  this  strategy  was
afe.  Indeed,  among  patients  who  experienced  a  MACE  in
he  copeptin  group,  only  two  patients  were  discharged  from
he  ED  early  (0.6%).  No  MI  or  death  occurred  in  the  dis-
harge  copeptin-negative  patients  of  the  copeptin  group.
he  authors  concluded  that,  with  an  attentive  clinical  exam-
nation  and  risk  stratiﬁcation  (i.e.  low-to-intermediate)
n  patients  presenting  with  a  suspected  ACS,  those  with
egative  troponin  and  negative  copeptin  could  safely  be
ischarged  from  ED.  This  strategy  therefore  allowed  a  sig-
iﬁcant  reduction  in  the  length  of  hospital  stay.  One  major
imitation  of  the  study  should,  however,  be  highlighted:
here  was  a  high  number  of  cross-overs  (n  =  71)  in  the
opeptin-negative  group.  Therefore,  the  results  of  this  study
hould  be  interpreted  with  caution.
A  recent  meta-analysis  [33],  which  included  all  but  the
iC-8  studies  (n  =  8740  patients),  was  published  in  2014.
hey  investigated  the  diagnostic  accuracy  of  copeptin  in
ombination  with  cardiac  troponin  to  rule  out  MI  in  ED.
his  meta-analysis  reported  that  the  use  of  copeptin  sig-
iﬁcantly  improved  the  sensitivity  (from  87  to  96%),  but
t  the  cost  of  a  decrease  in  speciﬁcity  (from  84  to  56%).
f  note,  the  sensitivity  improvement  was  less,  but  still  sig-
iﬁcantly  improved  (from  91  to  98%),  when  high-sensitivity
ardiac  troponin  T  was  used  as  the  reference  (Fig.  3).  In  this
ase,  the  speciﬁcity  was  also  signiﬁcantly  reduced  (from  75
o  50%).
(
pG.  Schurtz  et  al.
To  summarize,  copeptin  has  no  place  in  the  diagnosis
f  STEMI  (diagnostic  and  reperfusion  therapy  decisions  are
ased  on  ECG  alone)  or  in  ‘late  presenters’  after  CPO  in
uspected  NSTE-ACS  (diagnosis  can  be  based  on  troponins
lone).  The  use  of  copeptin  in  suspected  NSTE-ACS  has
een  shown  to  slightly  improve  the  sensitivity  and  NPV  of
roponins  in  ‘early  presenters’  after  CPO  (<3  hours)  even
hen  a  high-sensitivity  troponin  is  used  as  the  reference,
ut  at  the  cost  of  a  decrease  in  speciﬁcity  [33,34].  The
ossibility  of  a  safe  early  discharge  should,  however,  be
etter  demonstrated  before  widely  recommending  such  a
trategy  in  clinical  practice  [35].  In  addition,  adapting  ther-
pies  and  management  on  the  result  of  copeptin  dosage
as  not  been  adequately  studied  and  should  be  further
xplored.  Therefore,  routine  copeptin  use  in  ‘early  pre-
enters’  is  not  currently  recommended  [36]  due  to  a  lack
f  robust  data  showing  a  relevant  additional  value  com-
ared  to  high-sensitivity  troponins.  According  to  the  latest
uidelines  [36]  a  unique  measurement  of  high-sensitivity
roponins  below  the  99th  percentile  can  allow  immediate
ischarge.
opeptin in HF
espite  recent  improvements,  the  prognostic  evaluation  of
atients  with  stable  but  severe  chronic  systolic  HF  remains
 critical  and  imperfect  issue  in  clinical  practice.  Due  to
he  lack  of  heart  transplants  in  real  life  and  the  relatively
igh-risk  of  serious  adverse  complications  related  to  car-
iac  assistance  and  cardiac  transplantation,  it  is  important
o  identify  those  patients  who  may  beneﬁt  the  most  from
uch  therapies.
Several  trials  have  shown  that  copeptin  is  a  promising
redictor  of  outcomes  in  acute  and  chronic  HF  (Table  3).
toiser  et  al.  [37]  were  the  ﬁrst  to  compare  copeptin
ith  the  usual  natriuretic  peptides  in  a cohort  of  268
atients  with  advanced  decompensated  HF.  All  patients
ere  NYHA  functional  class  III  or  IV.  The  observation  period
as  15.8  ±  6.6  months.  Of  these  268  patients,  83  died  during
ollow-up  and  122  experienced  worsening  of  HF  (145  patients
eached  the  combined  endpoint  of  death  or  worsening  of
F).  In  multivariable  analyses,  copeptin  was  an  indepen-
ent  predictor  of  mortality  (P  <  0.0001),  re-hospitalization
or  HF  (P  =  0.05)  and  the  combined  endpoint  (P  <  0.0001).
opeptin  was  superior  to  BNP  for  predicting  mortality  and
he  combined  endpoint,  but  BNP  was  the  best  predictor  for
e-hospitalization  due  to  HF.  The  authors  concluded  that
easurement  of  copeptin  is  a  good  marker  to  predict  out-
omes  in  patients  with  decompensated  HF,  and  could  be
uperior  to  natriuretic  peptides.
However,  the  predictive  value  of  copeptin  in  the  entire
pectrum  of  HF  is  not  clear,  especially  in  patients  with  sta-
le  chronic  HF.  An  observational  study  published  in  2008
ncluded  786  such  patients  (mean  left  ventricular  ejection
raction  [LVEF]  25%)  [38].  After  the  2-year  follow-up,  233
atients  (30%)  had  experienced  all-cause  mortality.  A  mul-
ivariable  model  for  survival  showed  that  NYHA  functionalP  =  0.014)  predicted  death.  NYHA  class  was  the  strongest
redictor  of  death  and  this  variable  was  dichotomized  to
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Table  3  Major  studies  focusing  on  the  prognostic  value  of  copeptin  in  HF  patients.
Reference  Patients  Endpoint  and  results
Stoiser  et  al.,  2006  [37]  268  patients  with
decompensated  HF  (NYHA  III
or  IV)
Follow-up:  15.8  ±  6.6  months
Copeptin  independently  predicts  mortality  (P  <  0.0001),
re-hospitalization  for  HF  (P  =  0.05)  and  combined  endpoint
(P  <  0.0001)
It  was  superior  to  BNP  for  predicting  mortality  and
combined  endpoint
Neuhold  et  al.,  2008  [38]  786  patients  with  stable
chronic  HF  (mean  LVEF  25%)
Follow-up:  2  years
Copeptin  was  the  most  potent  predictor  of  all-cause  death
in  NYHA  II  (HR:  1.014,  95%  CI:  1.007—1.021;  P  =  0.0001)  and
NYHA  III  (HR:  1.010,  95%  CI:  1.003—1.017;  P  =  0.0039)
patients
It  was  superior  to  BNP  in  these  subgroups
Tentzeris  et  al.,  2011  [39]  172  patients  with  stable  HF  Follow-up:  42.5  months
High  copeptin  (>16.4  pmol/L)  was  an  independent  predictor
of  poor  outcome:  all-cause  mortality  and  hospitalization
for  HF  (HR:  2.51,  95%  CI:  1.66—3.79;  P  <  0.001)
It  was  even  more  discriminant  when  added  to  other
biomarkers  such  as  troponins  and  NT-proBNP
BNP: B-type natriuretic peptide; CI: conﬁdence interval; HF: heart failure; HR: hazard ratio; LVEF: left ventricular ejection fraction;
NT-proBNP: N-terminal pro-hormone B-type natriuretic peptide; NYHA: New York Heart Association.
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manalyse  the  predictive  value  of  copeptin  at  different  stages.
In  NYHA  II  and  III  patients,  copeptin  was  the  most  potent
single  predictor  of  death  (P  =  0.0001  and  P  =  0.0039,  respec-
tively),  whereas  in  stage  IV  patients,  sodium  level  and
glomerular  ﬁltration  rate  were  the  most  powerful  predic-
tors  of  mortality  and  copeptin  did  not  show  any  additional
value  in  this  subgroup.
Tentzeris  et  al.  [39]  investigated  the  combined  role  of
copeptin  and  cardiac  troponin  T  to  identify  high-risk  patients
with  stable  chronic  HF  (n  =  172).  LVEF  was  <45%  in  all  cases
and,  for  55.8%  of  the  patients,  was  <35%.  The  primary
endpoint  was  a  composite  of  all-cause  mortality  or  hos-
pitalization  for  decompensated  HF.  High  troponin  T  was  a
signiﬁcant  predictor  of  poor  outcome  (hazard  ratio  [HR]
2.96,  95%  conﬁdence  interval  [CI]  1.88—4.64;  P  <  0.001),
as  was  high  copeptin  level  (HR:  2.51,  95%  CI:  1.66—3.79;
P  <  0.001).  A  copeptin  level  >16.4  pg/mL  was  an  independent
predictor  of  worse  outcome  (adjusted  for  age,  sex,  NYHA
class,  renal  function  and  plasma  level  of  NT-proBNP).  Adding
copeptin  to  other  biomarkers  improved  model  discrimina-
tion.  Patients  with  increased  levels  of  both  parameters
(troponin  T  and  copeptin)  had  higher  rates  of  mortality
and  adverse  events.  The  authors  concluded  that,  in  associa-
tion  with  troponin  T,  copeptin  could  help  physicians  identify
patients  at  risk  of  death  or  acute  HF.
To  summarize,  copeptin  looks  promising  for  the  risk  strat-
iﬁcation  improvement  of  patients  with  chronic  systolic  HF.
However,  this  biomarker  and  its  incremental  value  on  top  of
‘classic’  prognostic  indicators  (NYHA  class,  LVEF,  BNP,  creati-
nine,  VO2 max)  need  to  be  further  validated  in  large  studies
and,  for  now,  physicians’  decisions  cannot  rely  on  copeptin
levels  in  routine  practice.  To  the  best  of  our  knowledge,  no
I
o
o
trial  has  studied  the  predictive  value  of  copeptin  in  HF  with
reserved  ejection  fraction.
uture directions and multimarker
pproach
iomarkers  can  provide  important  information  for  diag-
ostic,  prognostic  and  therapeutic  strategies  and  their
elated  adverse  events.  Although  these  markers  offer  great
pportunities,  they  are  related  to  various  physiopatho-
ogical  processes  and  clinical  presentations.  A perfect
ingle  biomarker  is  very  unlikely  to  be  found,  but  a
ultimarker  approach,  where  each  biomarker  provides
nsight  into  various  underlying  pathways,  could  be  a  pow-
rful  tool  for  tailored  and  targeted  therapies  in  each
atient  [28].  A  tandem  approach  with  biomarkers  and
thers  multimodal  or  imaging  tools  should  also  provide
dditional  risk  stratiﬁcation  and  evaluation  of  disease
rogression  before  symptom  onset,  thus  allowing  more
ffective  preventive  strategies.  The  ultimate  goal  would  be
o  improve  patient  outcomes  rather  than  creating  greater
omplexity.
Several  trials  have  assessed  the  diagnostic  and  progno-
tic  value  of  copeptin  in  various  cardiovascular  diseases,
specially  HF  and  ACS.  Primary  results  show  that  copeptin
s  promising  for  the  risk  stratiﬁcation  of  HF  patients  and  the
anagement  of  patients  who  present  at  ED  early  after  CPO.t  should,  however,  be  emphasized  that  the  additional  value
f  copeptin  over  high-sensitivity  troponins  remains  a  matter
f  debate.  Further  studies  are  required  to  precisely  deﬁne
he  speciﬁc  role  of  copeptin  in  chronic  HF  and  ACS.  For  now,
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uidelines  do  not  recommend  the  systematic  use  of  copeptin
n  these  settings.
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